Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma

Published:2012-10-23 Issue:5 Volume:119 Page:971-977
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Petrucci Maria Teresa,Levi Anna,Bringhen Sara,Scotti Simona,Gentilini Fabiana,Russo Simone,Siniscalchi Agostina,Larocca Alessandra,Grammatico Sara,Boccadoro Mario,Foà Robin,Palumbo Antonio

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27820/fullpdf

Reference26 articles.

1. Treatment for multiple myeloma: combination chemotherapy with different Melphalan doses regimens;Alexanian;JAMA.,1969

2. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after 1 prior therapy;Kane;Clin Cancer Res.,2006

3. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents;Ma;Clin Cancer Res.,2003

4. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial;Mateos;J Clin Oncol.,2010

5. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial;Richardson;Blood.,2007

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endoplasmic Reticulum Stress and Emerging Therapeutic Targets in Cancer;Handbook of Cancer and Immunology;2023

2. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial;American Journal of Hematology;2021-04-12

3. Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia;Slovenian Journal of Public Health;2020-04-06

4. Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma;Journal of Blood Medicine;2018-01

5. Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study;Leukemia & Lymphoma;2017-04-12